TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report published on Saturday morning. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Performance

TXMD stock opened at $1.66 on Friday. The company’s 50 day moving average price is $1.74 and its 200 day moving average price is $1.91. TherapeuticsMD has a fifty-two week low of $1.43 and a fifty-two week high of $3.07.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter. The business had revenue of $0.23 million for the quarter.

Hedge Funds Weigh In On TherapeuticsMD

Several hedge funds have recently added to or reduced their stakes in TXMD. Prosperity Consulting Group LLC acquired a new stake in shares of TherapeuticsMD in the first quarter valued at approximately $56,000. Clearline Capital LP boosted its holdings in shares of TherapeuticsMD by 18.9% in the second quarter. Clearline Capital LP now owns 636,622 shares of the company’s stock valued at $1,025,000 after acquiring an additional 101,282 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of TherapeuticsMD in the fourth quarter valued at approximately $612,000. 30.74% of the stock is currently owned by hedge funds and other institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.